The treatment of chronic kidney disease aims at delay the progress of this disease

the treatment of chronic kidney disease aims at delay the progress of this disease

If youget early and effective treatment of chronic Kidney disease was always ongoing development and, ultimately, end-stage renal disease. Thus, existing kidney disease (such as chronic glomerulonephritis, lupus nephritis, etc.) may cause kidney damage or disease (such as diabetes, hypertension, etc.) must be effectively treated to prevent the occurrence of chronic renal failure; for early, chronic kidney disease need to be more active mid-treatment, in order to delay or prevent the occurrence of uremia.

chronic kidney disease

Macroalbuminuria, persistent hypertension associated with the rate of decline in GFR; but not sufficient evidence to support the correction of anemia, lipid-lowering therapy and low-protein diet can delay the progression of renal disease. UKPDS study confirmed that strict control of blood pressure can reduce 24% of diabetes-related complications, microvascular complications by 37% or even more stringent than the buck hypoglycemic strict sense. Proteinuria is considered to be a sign of diabetic nephropathy, has a large number of biopsy confirmed the information, type 1 diabetes and microalbuminuria in patients with early diabetes. An independent risk factor for kidney disease. Urinary albumin levels may reflect the severity of glomerular lesions. At present, a large number of clinical trials of angiotensin-converting enzyme inhibitors (ACEI) and angiotensin receptor blockers (ARB) can delay the progression of renal disease. ACEI and ARB in addition to lower system pressure, but also can reduce the capillary pressure and decrease protein filtration, but also reduce the benefits of angiotensin Ⅱ mediated cell proliferation and fibrosis.

Two relatively ARB and traditional antihypertensive therapy on the progression of diabetic nephropathy and --INNT randomized clinical trials have shown a benefit RENAAL ARB's. A meta-analysis of a collection of 11 randomized clinical trials, ACEI group showed better blood pressure control, urinary protein excretion rate, doubling the risk of kidney failure and baseline serum creatinine of 30% reduction in the combined end point. A recent national study also prompted ESBARI ACEI can reduce late (CKIN period, SCr≥3mg / d1) the development of chronic kidney disease to ESRD dangerous (43%); and CKD4

New immunosuppressants such as FK506, leflunomide and mycophenolate mofetil (MMF) and so by affecting intracellular signal transduction pathways, such as bypass selectively inhibit T helper cells and T cytotoxic effector cells, has been widely used treatment of refractory renal disease, tumor wolf Pi nephritis, vasculitis and primary lgA nephropathy, reduce urinary protein, slow the progression of kidney disease has made significant effect. But its long-term efficacy and safety are all effective dose to be further confirmed.